Fresh funding for Regenosca

Regenosca developed and patented TissueSpan, a technology which allows for the creation of off-the-shelf and ready-to-use regenerative implants that serve as a noninvasive alternative to patients’ tissue grafts. The current gold-standard procedure involves open surgery and the harvesting of a patient's own inner mouth tissue for grafting, and simpler endoscopic treatments have up to 80% failure rates. Regenosca’s tissues are designed to prevent a second surgical site for tissue harvesting, reducing pain, complications, and surgery time for patients.

The first indication is Urethral reconstruction, which is required to address a narrowed urinary passage, a so-called urethral stricture, which affects up to a million patients a year in the U.S. Results from its first-in-man study for urethral strictures confirmed the effectiveness of tissue healing at the implantation site, with perfect regrowth of the patients’ own tissue.

Regenosca has successfully raised CHF 1 million from private investors, Business Angels Switzerland, and Venture Kick. “This funding will allow us to demonstrate endoscopic delivery of TissueSpan”, said Eva-Maria Balet, CEO and co-founder. “This new approach will revolutionize the treatment of urethral stricture. An off-the-shelf implant instead of the patient’s own tissue. A simple endoscopic procedure instead of complex open surgery.”

Besides the positive clinical developments, Regenosca has gained market traction and received support from organizations like Venture Kick and the Gebert Rüf Foundation, as well as won awards at the three biggest urology conferences globally: the European Association of Urology, the Société Internationale d’Urologie, and the American Urological Association.

This news follows the recent appointment of Aydin Kurt-Elli to Regenosca’s Board of Directors. His entrepreneurial experience, knowledge in healthcare and vast network will be of great value to grow the company to the next stage.

(Press release/RAN)